Tifacogin, Recombinant Tissue Factor Pathway Inhibitor

被引：66

作者：

Matyal, Robina ^{[1
]}

Mahmood, Feroze ^{[1
]}

Park, Kyung W. ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Crit Care & Pain Med, Dept Anesthesia, Boston, MA 02215 USA

来源：

INTERNATIONAL ANESTHESIOLOGY CLINICS | 2005年 / 43卷 / 02期

关键词：

D O I：

10.1097/01.aia.0000157499.41843.a3

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

[No abstract available]

引用

页码：135 / 144

页数：10

共 34 条

[1] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].

Abraham, E ;

Reinhart, K ;

Svoboda, P ;

Seibert, A ;

Olthoff, D ;

Dal Nogare, A ;

Postier, R ;

Hempelmann, G ;

Butler, T ;

Martin, E ;

Zwingelstein, C ;

Percell, S ;

Shu, V ;

Leighton, A ;

Creasey, AA .

CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089

[2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].

Abraham, E ;

Reinhart, K ;

Opal, S ;

Demeyer, I ;

Doig, C ;

Rodriguez, AL ;

Beale, R ;

Svoboda, P ;

Laterre, PF ;

Simon, S ;

Light, B ;

Spapen, H ;

Stone, J ;

Seibert, A ;

Peckelsen, C ;

De Deyne, C ;

Postier, R ;

Pettilä, V ;

Sprung, CL ;

Artigas, A ;

Percell, SR ;

Shu, V ;

Zwingelstein, C ;

Tobias, J ;

Poole, L ;

Stolzenbach, JC ;

Creasey, AA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247

[3] Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review [J].

Vincent, JL ;

Abraham, E ;

Esmon, C ;

Hack, CE .

CRITICAL CARE MEDICINE, 2000, 28 (09) :S33-S33

[4]

Amirkhosravi A, 2002, THROMB HAEMOSTASIS, V87, P930

[5] Unraveling severe sepsis - Why did OPTIMIST fail and what's next? [J].

Angus, DC ;

Crowther, MA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :256-258

[6] Tissue-factor antigen and activity in human coronary atherosclerotic plaques [J].

Ardissino, D ;

Merlini, PA ;

Ariens, R ;

Coppola, R ;

Bramucci, E ;

Mannucci, PM .

LANCET, 1997, 349 (9054) :769-771

[7] Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques - Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions [J].

Badimon, JJ ;

Lettino, M ;

Toschi, V ;

Fuster, V ;

Berrozpe, M ;

Chesebro, JH ;

Badimon, L .

CIRCULATION, 1999, 99 (14) :1780-1787

[8]

Bajaj MS, 1997, THROMB HAEMOSTASIS, V78, P471

[9] TISSUE FACTOR PATHWAY INHIBITOR AND THE CURRENT CONCEPT OF BLOOD-COAGULATION [J].

BROZE, GJ .

BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 :S7-S13

[10]

CALLANDER NS, 1992, CANCER-AM CANCER SOC, V70, P1194, DOI 10.1002/1097-0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO

← 1 2 3 4 →